| pubmed-article:9033641 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9033641 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:9033641 | lifeskim:mentions | umls-concept:C0596638 | lld:lifeskim |
| pubmed-article:9033641 | lifeskim:mentions | umls-concept:C0001563 | lld:lifeskim |
| pubmed-article:9033641 | lifeskim:mentions | umls-concept:C0332161 | lld:lifeskim |
| pubmed-article:9033641 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:9033641 | lifeskim:mentions | umls-concept:C0221099 | lld:lifeskim |
| pubmed-article:9033641 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:9033641 | lifeskim:mentions | umls-concept:C1332714 | lld:lifeskim |
| pubmed-article:9033641 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:9033641 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:9033641 | lifeskim:mentions | umls-concept:C0072522 | lld:lifeskim |
| pubmed-article:9033641 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9033641 | pubmed:dateCreated | 1997-3-6 | lld:pubmed |
| pubmed-article:9033641 | pubmed:abstractText | We investigated both the effect and the mechanism of oral (p.o.) administration of PSK, a protein-bound polysaccharide derived from Basidiomycetes, on the anti-tumor T-cell response in gut-associated lymphoid tissue (GALT). The p.o. administration of PSK significantly suppressed the growth of colon 26 carcinoma (C-26) inoculated into the subserosal space of the cecum (i.c.), and augmented the tumor-neutralizing activity of the draining mesenteric lymph node (LN) cells. PSK treatment also significantly decreased the levels of immunosuppressive factors such as plasma transforming growth factor (TGF)-beta in the i.c. C-26-inoculated mice. We also evaluated the improving effect of PSK on the anti-tumor T-cell response in GALT by utilizing B7-transfected P815 mastocytoma (B7/P815). The PSK treatment promoted the rejection of i.c.-inoculated B7/P815 and restored the CD4+ T-cell-dependent proliferative response of the draining mesenteric LN cells against in vitro restimulation. Furthermore, the treatment also decreased the TGF-beta production but increased the IFN-gamma production of these cells. The p.o. administration of PSK, however, showed no effect in the CD8+ T-cell-dependent cytolytic activity of the draining mesenteric LN cells after in vitro restimulation. Overall, these results indicate that the p.o. administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in GALT, mainly through a suppression of TGF-beta production and a restoration of IFN-gamma production. | lld:pubmed |
| pubmed-article:9033641 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9033641 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9033641 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9033641 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9033641 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9033641 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9033641 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9033641 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9033641 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9033641 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9033641 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9033641 | pubmed:issn | 0020-7136 | lld:pubmed |
| pubmed-article:9033641 | pubmed:author | pubmed-author:KimuraGG | lld:pubmed |
| pubmed-article:9033641 | pubmed:author | pubmed-author:AbeKK | lld:pubmed |
| pubmed-article:9033641 | pubmed:author | pubmed-author:NomotoKK | lld:pubmed |
| pubmed-article:9033641 | pubmed:author | pubmed-author:IijimaHH | lld:pubmed |
| pubmed-article:9033641 | pubmed:author | pubmed-author:HaradaMM | lld:pubmed |
| pubmed-article:9033641 | pubmed:author | pubmed-author:MatsunagaKK | lld:pubmed |
| pubmed-article:9033641 | pubmed:author | pubmed-author:ItoOO | lld:pubmed |
| pubmed-article:9033641 | pubmed:author | pubmed-author:TamadaKK | lld:pubmed |
| pubmed-article:9033641 | pubmed:author | pubmed-author:OguchiYY | lld:pubmed |
| pubmed-article:9033641 | pubmed:author | pubmed-author:TakenoyamaMM | lld:pubmed |
| pubmed-article:9033641 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9033641 | pubmed:day | 27 | lld:pubmed |
| pubmed-article:9033641 | pubmed:volume | 70 | lld:pubmed |
| pubmed-article:9033641 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9033641 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9033641 | pubmed:pagination | 362-72 | lld:pubmed |
| pubmed-article:9033641 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:meshHeading | pubmed-meshheading:9033641-... | lld:pubmed |
| pubmed-article:9033641 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9033641 | pubmed:articleTitle | Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice. | lld:pubmed |
| pubmed-article:9033641 | pubmed:affiliation | Department of Virology, Kyushu University, Fukuoka, Japan. harada@bioreg.kyushu-u.ac.jo | lld:pubmed |
| pubmed-article:9033641 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9033641 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9033641 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9033641 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9033641 | lld:pubmed |
